指南与共识妇科肿瘤

美国癌症协会2020年一般风险人群宫颈癌筛查指南更新

Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society.
指南 / 共识 · CA Cancer J Clin · 2020-07-30

美国癌症协会(ACS)更新一般风险人群宫颈癌筛查指南:推荐25岁开始筛查,首选每5年一次HPV初筛直至65岁;若不可及,可选每5年联合检测或每3年细胞学检查。>65岁且过去25年无CIN2+史、过去10年筛查充分阴性者可停止筛查。指南为过渡性,待HPV初筛可及后应逐步淘汰联合检测和细胞学。

要点

  • 25岁起筛查,首选每5年HPV初筛至65岁。
  • HPV初筛不可及时,可选每5年联合检测或每3年细胞学。
  • >65岁满足特定条件可停止筛查。

核心结论

  • ACS推荐一般风险人群25岁起筛查,首选每5年HPV初筛至65岁;若不可及,可选每5年联合检测或每3年细胞学。
  • >65岁且过去25年无CIN2+史、过去10年筛查充分阴性者可停止筛查。
  • 指南为过渡性,待HPV初筛可及后应逐步淘汰联合检测和细胞学。

研究设计与样本

  • ACS基于证据回顾制定的一般风险人群宫颈癌筛查指南更新。

主要发现

  • 与2012版相比有4点不同:首选每5年HPV初筛;起始年龄25岁而非21岁;25岁起即可HPV初筛而非30岁;指南为过渡性。
  • 筛查间隔、停止筛查年龄或标准、基于疫苗接种状态的筛查、子宫切除后筛查的推荐未改变。
  • HPV和/或细胞学阳性者的随访应遵循2019年ASCCP基于风险的管理共识指南。

关键数值与推荐

  • 首选:25-65岁每5年一次HPV初筛(强推荐)。
  • 可接受:25-65岁每5年联合检测或每3年细胞学(强推荐)。
  • >65岁停止筛查需过去25年无CIN2+史且过去10年筛查充分阴性(限定推荐)。

临床怎么用

  • 对一般风险人群,首选HPV初筛,间隔5年。
  • HPV初筛不可及时,采用联合检测每5年或细胞学每3年。
  • 筛查阳性者按2019年ASCCP风险based管理共识随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The American Cancer Society (ACS) recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 years through age 65 years (preferred); if primary HPV testing is not available, then individuals aged 25 to 65 years should be screened with cotesting (HPV testing in combination with cytology) every 5 years or cytology alone every 3 years (acceptable) (strong recommendation). The ACS recommends that individuals aged >65 years who have no history of cervical intraepithelial neoplasia grade 2 or more severe disease within the past 25 years, and who have documented adequate negative prior screening in the prior 10 years, discontinue all cervical cancer screening (qualified recommendation). These new screening recommendations differ in 4 important respects compared with the 2012 recommendations: 1) The preferred screening strategy is primary HPV testing every 5 years, with cotesting and cytology alone acceptable where access to US Food and Drug Administration-approved primary HPV testing is not yet available; 2) the recommended age to start screening is 25 years rather than 21 years; 3) primary HPV testing, as well as cotesting or cytology alone when primary testing is not available, is recommended starting at age 25 years rather than age 30 years; and 4) the guideline is transitional, ie, options for screening with cotesting or cytology alone are provided but should be phased out once full access to primary HPV testing for cervical cancer screening is available without barriers. Evidence related to other relevant issues was reviewed, and no changes were made to recommendations for screening intervals, age or criteria for screening cessation, screening based on vaccination status, or screening after hysterectomy. Follow-up for individuals who screen positive for HPV and/or cytology should be in accordance with the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020. PMID: 32729638. doi:10.3322/caac.21628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。